Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
Harpoon Therapeutics, Inc. (HARP)
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data presented earlier today at ASCO from the ongoing dose escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration resistant prostate cancer (mCRPC). Harpoon has four product candidates in c
Show less
Read more
Impact Snapshot
Event Time:
HARP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HARP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HARP alerts
High impacting Harpoon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HARP
News
- Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]Seeking Alpha
- Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.MarketBeat
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNWGlobeNewswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – HARP, FGH, BBAIAccesswire
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TASTPR Newswire
HARP
Sec Filings
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- HARP's page on the SEC website